Citation, DOI, disclosures and article data
macrocyclic, non-ionic molecule
100% renally excreted
T1 relaxivity: 12.8 mM·s at 1.5 T and 11.6 mM·s at 3 T
concentration: 0.5 mmol/mL
recommended dosage: 0.05 mmol/kg
As a new extracellular contrast agent, the MRI studies for which gadopiclenol may be useful are still being explored. It has potential for a wide range of studies of both the CNS and body.
Gadopiclenol has a much higher T1 relaxivity than other GBCAs currently used, and therefore can be used at a lower dosage and this is felt to be one of its main strengths. It may reduce the potential risk attributed to deposition of free gadolinium in soft tissues as there will be less gadolinium to be deposited.
- 1. Robic C, Port M, Rousseaux O et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol. 2019;54(8):475-84. doi:10.1097/RLI.0000000000000563 - Pubmed
- 2. Hao J, Bourrinet P, Desché P. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). Invest Radiol. 2019;54(7):396-402. doi:10.1097/RLI.0000000000000556 - Pubmed
- 3. Robert P, Vives V, Grindel A et al. Contrast-To-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-Based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model. Radiology. 2020;294(1):117-26. doi:10.1148/radiol.2019182953 - Pubmed